Baxter announced that the Food and Drug Administration (FDA) has approved Phoxillum Renal Replacement Solutions (BK4/2.5 and B2K4/0) for use in continuous renal replacement therapy (CRRT) to replace plasma volume removed by ultrafiltration, correct electrolyte and acid-base imbalances, and for use in drug poisoning when CRRT is used to remove dialyzable substances.
Phoxillum is the only approved pre-mixed solution containing phosphate in a 5000mL bag. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations . The bicarbonate present in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.
Phoxillum is available in a 2-compartment 5000mL bag containing different bicarbonate concentrations. It is anticipated to launch in the second quarter of 2015.
For more information call (800) 422-9837 or visit Baxter.com.